Synthesis of novel 17-(4′-formyl)pyrazolylandrosta-5,16-dienes and their derivatives as potent 17α-hydroxylase/C17,20-lyase inhibitors or antiproliferative agents depending on the substitution pattern of the heteroring

European Journal of Medicinal Chemistry
2016.0

Abstract

A series of novel 17-(4'-formyl)pyrazolylandrosta-5,16-dienes were efficiently synthesized in two steps from pregnadienolone acetate with monosubstituted hydrazines via the cyclization/formylation sequence of the primarily formed hydrazones on treatment with the Vilsmeier-Haack reagent. The products were further transformed by deacetylation and subsequent reduction in order to enlarge the compound library available for pharmacological studies. Moreover, 4'-formylpyrazoles containing H or Me on the heteroring-N were subjected to oxime formation and Ac2O-induced dehydration to furnish the corresponding 4'-cyano derivatives in good yields. The antiproliferative activities of the structurally related steroidal 17-exo-pyrazole derivatives were tested in vitro on four human adherent breast cancer cell lines (MCF7, T47D, MDA-MB-231 and MDA-MB-361): the microculture tetrazolium assay revealed that seven compounds exerted better cell growth-inhibitory effects on some or all these cell lines than those of the reference cisplatin. With regard to the well-known structural features that a potent C17,20-lyase inhibitor should possess, some relevant derivatives were tested in vitro from the aspects of their inhibitory effects on rat testicular enzyme, and one of them proved to exert noteworthy enzyme-inhibitory action, with an IC50 (26 nM) of the same order of magnitude as that of abiraterone.

Knowledge Graph

Similar Paper

Synthesis of novel 17-(4′-formyl)pyrazolylandrosta-5,16-dienes and their derivatives as potent 17α-hydroxylase/C17,20-lyase inhibitors or antiproliferative agents depending on the substitution pattern of the heteroring
European Journal of Medicinal Chemistry 2016.0
An efficient approach to novel 17-5′-(1′,2′,4′)-oxadiazolyl androstenes via the cyclodehydration of cytotoxic O-steroidacylamidoximes, and an evaluation of their inhibitory action on 17α-hydroxylase/C17,20-lyase
European Journal of Medicinal Chemistry 2013.0
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens:  Synthesis, in Vitro Biological Activity, Pharmacokinetics, and Antitumor Activity in the LAPC4 Human Prostate Cancer Xenograft Model
Journal of Medicinal Chemistry 2005.0
Novel Steroidal Inhibitors of Human Cytochrome P45017.alpha.-Hydroxylase-C17,20-lyase): Potential Agents for the Treatment of Prostatic Cancer
Journal of Medicinal Chemistry 1995.0
Synthesis and Evaluation of Novel Steroidal Oxime Inhibitors of P450 17 (17α-Hydroxylase/C17−20-Lyase) and 5α-Reductase Types 1 and 2
Journal of Medicinal Chemistry 2000.0
Synthesis and Evaluation of Pregnane Derivatives as Inhibitors of Human Testicular 17α-Hydroxylase/C<sub>17,20</sub>-Lyase<sup>,</sup>
Journal of Medicinal Chemistry 1996.0
Synthesis and Evaluation of 17-Aliphatic Heterocycle-Substituted Steroidal Inhibitors of 17α-Hydroxylase/C17−20-Lyase (P450 17)
Journal of Medicinal Chemistry 2000.0
Novel 17-Azolyl Steroids, Potent Inhibitors of Human Cytochrome 17α-Hydroxylase-C<sub>17,20</sub>-lyase (P450<sub>17</sub><sub>α</sub>):  Potential Agents for the Treatment of Prostate Cancer
Journal of Medicinal Chemistry 1998.0
17-Imidazolyl, Pyrazolyl, and Isoxazolyl Androstene Derivatives. Novel Steroidal Inhibitors of Human Cytochrome C<sub>l7,20</sub>-Lyase (P450<sub>17α</sub>)
Journal of Medicinal Chemistry 1997.0
17(E)-Picolinylidene androstane derivatives as potential inhibitors of prostate cancer cell growth: Antiproliferative activity and molecular docking studies
Bioorganic &amp; Medicinal Chemistry 2013.0